Share
VIDEOS 1 TO 50
Acorda Therapeutics CEO: High-Powered Biotech | Mad Money | CNBC
Acorda Therapeutics CEO: High-Powered Biotech | Mad Money | CNBC
Published: 2015/01/13
Channel: CNBC
Ron Cohen: The new world of patient engagement
Ron Cohen: The new world of patient engagement
Published: 2016/07/13
Channel: McKinsey & Company
Acorda Therapeutics 100% virtualized environment
Acorda Therapeutics 100% virtualized environment
Published: 2012/11/05
Channel: VMware
Acorda Therapeutics, Inc - 2014 Small Business Award
Acorda Therapeutics, Inc - 2014 Small Business Award
Published: 2014/04/29
Channel: Business Council of Westchester
Acorda Therapeutics CEO Ron Cohen, MD takes the ALS ice bucket challenge
Acorda Therapeutics CEO Ron Cohen, MD takes the ALS ice bucket challenge
Published: 2014/08/15
Channel: Michael Russo
Syncplicity Success Story | Acorda Therapeutics
Syncplicity Success Story | Acorda Therapeutics
Published: 2015/01/16
Channel: Syncplicity by Axway
Syncplicity Customer Success Program | Driving User Adoption at Acorda Therapeutics
Syncplicity Customer Success Program | Driving User Adoption at Acorda Therapeutics
Published: 2014/10/07
Channel: Syncplicity by Axway
Acorda Therapeutics
Acorda Therapeutics
Published: 2016/03/14
Channel: Why Invest In
Acorda Therapeutics
Acorda Therapeutics
Published: 2016/11/22
Channel: Why Invest In
Interview: Ann Schaefer, Acorda Therapeutics | Pharma TRACKTS! 2016
Interview: Ann Schaefer, Acorda Therapeutics | Pharma TRACKTS! 2016
Published: 2017/04/13
Channel: we.MEDIA – The Content Delivery Network
The First Take: Acorda acquires Biotie Therapeutics
The First Take: Acorda acquires Biotie Therapeutics
Published: 2016/01/19
Channel: FirstWordPharma
Acorda Therapeutics
Acorda Therapeutics
Published: 2017/02/10
Channel: Why Invest In
Acorda Therapeutics wins the first of two 2011 Stevie Awards
Acorda Therapeutics wins the first of two 2011 Stevie Awards
Published: 2011/06/30
Channel: TheStevies
Acorda Therapeutics Disaster Recovery Strategy with VMware SRM
Acorda Therapeutics Disaster Recovery Strategy with VMware SRM
Published: 2012/11/05
Channel: VMware
Acorda Therapeutics on EMC VSPEX
Acorda Therapeutics on EMC VSPEX
Published: 2013/09/09
Channel: Dell EMC
Acorda Therapeutics
Acorda Therapeutics
Published: 2013/03/17
Channel: JournalNewsReporter
Acorda Therapeutics, Inc. wins 2012 Gold Stevie Award
Acorda Therapeutics, Inc. wins 2012 Gold Stevie Award
Published: 2012/09/27
Channel: TheStevies
Kyle Bass Hits A Snag on Acorda Therapeutics
Kyle Bass Hits A Snag on Acorda Therapeutics
Published: 2015/08/27
Channel: Mimesis Law
FirstWord Pharma Daily News Round-Up Video for February 9, 2017
FirstWord Pharma Daily News Round-Up Video for February 9, 2017
Published: 2017/02/09
Channel: FirstWordPharma
Acorda Therapeutics (NASDAQ:ACOR) Stock Trading Idea: 15.6% Return in 3 Months
Acorda Therapeutics (NASDAQ:ACOR) Stock Trading Idea: 15.6% Return in 3 Months
Published: 2010/01/25
Channel: TradeTheTrend
Spotlight - Acorda Therapeutics - Bloomberg
Spotlight - Acorda Therapeutics - Bloomberg
Published: 2009/07/01
Channel: Bloomberg
Ron Cohen: Digitizing collaboration and engagement
Ron Cohen: Digitizing collaboration and engagement
Published: 2016/07/13
Channel: McKinsey & Company
Today
Today's stock investment ideas based on news signals 06.06.17
Published: 2017/06/06
Channel: First to invest - stock news signals
Ron Cohen, President and CEO of Acorda Therapeutics, Inc.
Ron Cohen, President and CEO of Acorda Therapeutics, Inc.
Published: 2012/02/16
Channel: Biotechnology Innovation Organization
60-second Stories: Maya Srinivas, PhD, Acorda Therapeutics
60-second Stories: Maya Srinivas, PhD, Acorda Therapeutics
Published: 2017/03/29
Channel: Cellular Dynamics International
Acorda Therapeutics | Learn How I Turned $15,253 Into $1,613,442 Trading Biotech Stocks
Acorda Therapeutics | Learn How I Turned $15,253 Into $1,613,442 Trading Biotech Stocks
Published: 2017/03/02
Channel: Biotech Stocks 1202
Telecine Presents
Telecine Presents 'SynapseTV' @ Acorda Therapeutics
Published: 2015/09/28
Channel: Telecine Multimedia
News Update: Acorda Therapeutics (NASDAQ:ACOR) announce Ampyra Pricing
News Update: Acorda Therapeutics (NASDAQ:ACOR) announce Ampyra Pricing
Published: 2010/02/08
Channel: TradeTheTrend
Developing Cures, Creating Jobs in the Westchester/Hudson Valley Region
Developing Cures, Creating Jobs in the Westchester/Hudson Valley Region
Published: 2012/10/16
Channel: New York Health Works
Earnings Report: Acorda Therapeutics (NYSE:ACOR) Reports Inline Loss, Top Line Up 15.9%
Earnings Report: Acorda Therapeutics (NYSE:ACOR) Reports Inline Loss, Top Line Up 15.9%
Published: 2010/02/23
Channel: TradeTheTrend
Ron Cohen of Acorda Therapeutics wins a 2011 Stevie Award
Ron Cohen of Acorda Therapeutics wins a 2011 Stevie Award
Published: 2011/06/27
Channel: TheStevies
Technical Analysis: After Yesterday
Technical Analysis: After Yesterday's Rally of 4.27%, Acorda Therapeutics Shares Could Pullback
Published: 2010/05/13
Channel: TradeTheTrend
Being Money Smart - Financial Wellness Webinar Series
Being Money Smart - Financial Wellness Webinar Series
Published: 2012/09/06
Channel: National Disability Institute
Acorda Therapeutics Wins a Gold Stevie Award at The 2012 American Business Awards
Acorda Therapeutics Wins a Gold Stevie Award at The 2012 American Business Awards
Published: 2012/06/27
Channel: TheStevies
Acorda Therapeutics   Pipeline and Label Expansion of AMPYRA  Drivers of Growth - Reports Corner
Acorda Therapeutics Pipeline and Label Expansion of AMPYRA Drivers of Growth - Reports Corner
Published: 2013/07/17
Channel: reports corner
FirstWord Pharma Daily News Round-Up Video for August 25, 2015
FirstWord Pharma Daily News Round-Up Video for August 25, 2015
Published: 2015/08/25
Channel: FirstWordPharma
Ron Cohen - Meeting the Needs of Hypergrowth
Ron Cohen - Meeting the Needs of Hypergrowth
Published: 2016/12/06
Channel: Sensei Labs
How to Pronounce Acorda Therapeutics
How to Pronounce Acorda Therapeutics
Published: 2017/03/03
Channel: Emma Saying
Acorda
Acorda's Cohen Sees Demand Growth for MS Drug Ampyra: Video
Published: 2012/03/23
Channel: Bloomberg
How to say Acorda Therapeutics in English?
How to say Acorda Therapeutics in English?
Published: 2017/06/04
Channel: Learning Words
Cohen Says Acorda Is Looking to Develop New Drugs
Cohen Says Acorda Is Looking to Develop New Drugs
Published: 2011/06/27
Channel: Bloomberg
Working2Walk2011, Anthony Caggiano
Working2Walk2011, Anthony Caggiano
Published: 2012/09/02
Channel: unite2fightparalysis
WESEF 2105 montage for YouTube
WESEF 2105 montage for YouTube
Published: 2015/03/10
Channel: Michael Blueglass
Ron Cohen: Setting up your digital team for success
Ron Cohen: Setting up your digital team for success
Published: 2016/07/13
Channel: McKinsey & Company
Report: Mylan tied exec pay to aggressive profit targets
Report: Mylan tied exec pay to aggressive profit targets
Published: 2016/09/01
Channel: Fox Business
Ron Cohen: Embracing the digital vision
Ron Cohen: Embracing the digital vision
Published: 2016/07/13
Channel: McKinsey & Company
Ron Cohen: Adopting a test-and-learn approach
Ron Cohen: Adopting a test-and-learn approach
Published: 2016/07/13
Channel: McKinsey & Company
Ron_Cohen-"I am Biotech" Series
Ron_Cohen-"I am Biotech" Series
Published: 2012/11/03
Channel: drron1019
FirstWord Pharma Daily News Round-Up Video for January 19, 2016
FirstWord Pharma Daily News Round-Up Video for January 19, 2016
Published: 2016/01/19
Channel: FirstWordPharma
FirstWord Pharma Daily News Round-Up Video for April 3, 2017
FirstWord Pharma Daily News Round-Up Video for April 3, 2017
Published: 2017/04/03
Channel: FirstWordPharma
NEXT
GO TO RESULTS [51 .. 100]

WIKIPEDIA ARTICLE

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Acorda Therapeutics Inc.
Public
Traded as NASDAQACOR
S&P 600 Component
FWBCDG
Industry Health care
Biotechnology
Founded 1995 (1995)[1]
Founder Ron Cohen
Headquarters Ardsley, New York, United States
Key people
Ron Cohen (CEO)
Andrew R. Blight
Products Zanaflex
Ampyra
Qutenza
Revenue Increase US$292.2 Million (FY 2011)[2]
Increase US$35.1 Million (FY 2011)[2]
Increase US$30.6 Million (FY 2011)[2]
Total assets Increase US$379.5 Million (FY 2011)[2]
Total equity Increase US$205.2 Million (FY 2011)[2]
Number of employees
328 (February, 2012) [2]
Website Acorda.com

Acorda Therapeutics is a biotechnology company based in Ardsley, New York, USA. The company develops drugs to improve therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system.[3] Acorda manufactures and markets the drugs Zanaflex, Ampyra and Qutenza in the United States.

History[edit]

In September 2014 the company acquired Civitas Therapeutics for $525 million - gaining the Phase III Parkinson’s drug, CVT-301.[4]

In January 2016, the company acquired Finnish pharmaceutical company, Biotie Therapies, for $363 million. This gave the company control over Biotes sclerosing cholangitis drug, BTT1023.[5]

In November 2016, Acorda Therapeutics announced it was discontinuing development of dalfampridine, a drug intended for post-stroke walking difficulties, after a clinical trial failure. The discontinuation of the drug caused Acorda's shares to drop as much as 13.2%. Acorda shares have dropped 50.2% since January 2016.[6]

Corporate governance[edit]

As of December 31, 2013, the members of the board of directors of Acorda Therapeutics were:[7] Ron Cohen, Barry Greene, Peder K. Jensen, John P. Kelley, Sandra Panem, Lorin J. Randall, Steven M. Rauscher, and Ian F. Smith.

Products[edit]

Products on the market[edit]

Products under development[edit]

  • CVT-301
  • Plumiaz (discontinued May 20, 2016)

References[edit]

External links[edit]

Disclaimer

None of the audio/visual content is hosted on this site. All media is embedded from other sites such as GoogleVideo, Wikipedia, YouTube etc. Therefore, this site has no control over the copyright issues of the streaming media.

All issues concerning copyright violations should be aimed at the sites hosting the material. This site does not host any of the streaming media and the owner has not uploaded any of the material to the video hosting servers. Anyone can find the same content on Google Video or YouTube by themselves.

The owner of this site cannot know which documentaries are in public domain, which has been uploaded to e.g. YouTube by the owner and which has been uploaded without permission. The copyright owner must contact the source if he wants his material off the Internet completely.

Powered by YouTube
Wikipedia content is licensed under the GFDL and (CC) license